The Dual Role of Mesenchymal Stem Cells in Cancer Pathophysiology: Pro-Tumorigenic Effects versus Therapeutic Potential

Int J Mol Sci. 2023 Aug 31;24(17):13511. doi: 10.3390/ijms241713511.

Abstract

Mesenchymal stem/stromal cells (MSCs) are multipotent cells involved in numerous physiological events, including organogenesis, the maintenance of tissue homeostasis, regeneration, or tissue repair. MSCs are increasingly recognized as playing a major, dual, and complex role in cancer pathophysiology through their ability to limit or promote tumor progression. Indeed, these cells are known to interact with the tumor microenvironment, modulate the behavior of tumor cells, influence their functions, and promote distant metastasis formation through the secretion of mediators, the regulation of cell-cell interactions, and the modulation of the immune response. This dynamic network can lead to the establishment of immunoprivileged tissue niches or the formation of new tumors through the proliferation/differentiation of MSCs into cancer-associated fibroblasts as well as cancer stem cells. However, MSCs exhibit also therapeutic effects including anti-tumor, anti-proliferative, anti-inflammatory, or anti-oxidative effects. The therapeutic interest in MSCs is currently growing, mainly due to their ability to selectively migrate and penetrate tumor sites, which would make them relevant as vectors for advanced therapies. Therefore, this review aims to provide an overview of the double-edged sword implications of MSCs in tumor processes. The therapeutic potential of MSCs will be reviewed in melanoma and lung cancers.

Keywords: cancer; mesenchymal stem cells; stroma; therapies; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Carcinogenesis
  • Humans
  • Lung Neoplasms*
  • Melanoma*
  • Mesenchymal Stem Cells*
  • Multipotent Stem Cells
  • Tumor Microenvironment

Grants and funding

PG and EPI team members received financial support from the EPIGEN project research (grant number CPER FEDER 2019221-0022768).